Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Frequently asked questions
What sector does Revelation Biosciences Inc (REVBW) operate in?
Revelation Biosciences Inc belongs to the Healthcare sector and operates in the industry.
What is Revelation Biosciences Inc (REVBW) current stock price?
As of the latest data, Revelation Biosciences Inc stock price is $0.01, with a previous close of $0.01.
What is Revelation Biosciences Inc (REVBW) current market capitalization?
Revelation Biosciences Inc market cap is approximately 22.98 thousand.
What is Revelation Biosciences Inc (REVBW) Earnings Per Share (EPS)?
The trailing EPS is -$4.77.
What is Revelation Biosciences Inc (REVBW) EBITDA?
Revelation Biosciences Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.32 million.
Does Revelation Biosciences Inc (REVBW) pay dividends?
No. Revelation Biosciences Inc does not pay a dividend.
What is Revelation Biosciences Inc (REVBW) beta (volatility) score?
Revelation Biosciences Inc has a beta of -0.060, indicating lower volatility than the overall market.
